Abstracts patients with HDL-c <1 mmol/L, treatment with statin plus addon Niaspan ® was compared to statin monotherapy. Niaspan ® treatment effects were taken from several clinical trials as summarized in the European SPC. The second model (Markov) simulated the development of coronary heart disease events based on the Framingham risk formulae. Direct medical costs were accounted from a third-party payer perspective in the UK and expressed in pounds sterling (£). Annual discount rates of 3.5% were applied to clinical and cost outcomes. RESULTS: Niaspan ® was associated with improvements in mean discounted life expectancy in diabetic (0.32 years) and non-diabetic cohorts (0.29 years) compared to statin monotherapy. Similarly, improvements in quality-adjusted life expectancy of (diabetic) 0.26 and (non-diabetic) 0.23 quality-adjusted life years (QALYs) were projected. Niaspan ® was associated with increases in mean lifetime costs of £4492 (diabetic) and £4891 (non-diabetic) versus statin alone. This led to incremental cost-effectiveness ratios of £17,296 per QALY gained in the diabetic cohort and £21,150 in the non-diabetic cohort. CONCLUSIONS: Addition of Niaspan ® to statin treatment was cost-effective by generally accepted standards compared to statin monotherapy in patients with persistently low HDL-c in the UK. In patients with Type-2 diabetes and an associated high risk of CHD events, add-on therapy with Niaspan ® represented better value for money than in non-diabetic patients. Novo Nordisk A/S, Bagsvaerd, Denmark OBJECTIVES: To project the long-term clinical and cost outcomes associated with long-acting insulin analog treatment in patients with type-1 diabetes in an Austrian setting. METHODS: We used a published, validated and peer-reviewed computer simulation model of diabetes to project short-term clinical findings to evaluate long-term outcomes including quality-adjusted life expectancy, complication rates and direct medical costs. Clinical data have been derived from the PREDICTIVE study, an ongoing global post-marketing safety study, for a sub-group of patients with type-1 diabetes receiving long-acting insulin glargine (IGlar) in a basal/bolus treatment regimen at baseline and switched to long-acting insulin detemir (IDet). After 12 weeks of follow up, IDet-based basal/bolus treatment was associated with improvements in HbA1c (0.25%-points lower), reduced risk of hypoglycemic events (by 55%), and decreased body weight (0.27 kg) compared to IGlar-based treatment. Probabilities of complications and HbA1c-dependent adjustments were derived from the DCCT, Framingham, and WESDR studies (amongst others). Costs of treating complications were retrieved from published sources. Total direct costs (complications + treatment costs) were projected over patient lifetimes. Costs and outcomes were discounted at 3.5% per annum. RESULTS: Improved glycemic control, decreased hypoglycemic events and BMI with IDetbased basal/bolus therapy led to fewer diabetes-related complications and an increase in quality-adjusted life expectancy of 0.13 quality-adjusted life years (QALYs). IDet-based therapy was associated with slightly higher lifetime direct costs (€394 per patient) which led to an incremental cost-effectiveness ratio (ICER) of €3031 per QALY gained. CONCLUSIONS: Shortterm clinical benefits associated with IDet-based basal/bolus therapy were projected to lead to improvements in qualityadjusted life expectancy and fewer diabetes related complications than IGlar-based regimens. Incremental cost-effectiveness analysis indicated that, over patient lifetimes, IDet-based combinations would represent good value for money versus IGlar-based therapy in the Austrian setting. (SEK 286,467 [11,745]) than in patients receiving OHAs (SEK 272,752 [12,885]), a difference of SEK 13,716 [17,030], leading to an incremental cost-effectiveness ratio of SEK 32,736 per QALY gained. Sensitivity analysis showed that these findings were robust under variation in a range of assumptions. CONCLUSIONS: Switching to BIAsp 30 was projected to reduce the incidence of diabetes-related complications, and improve life expectancy and quality-adjusted life expectancy, compared to continuation of OHAs in Type-2 diabetes patients. Switching to BIAsp 30 was projected to represent good value for money by internationally accepted standards in the Swedish setting. In patients with type-1 diabetes, poor glycemic control is associated with an increased risk of complications. A recent clinical study provided evidence that basal/bolus treatment with insulin detemir + insulin aspart (IDet/IAsp) improved HbA1c (0.22%-points lower after 18 weeks), reduced the risk of hypoglycemic events (by 21%), and decreased body mass index
Novo Nordisk A/S, Bagsvaerd, Denmark OBJECTIVES: To project the long-term clinical and cost outcomes associated with long-acting insulin analog treatment in patients with type-1 diabetes in an Austrian setting. METHODS: We used a published, validated and peer-reviewed computer simulation model of diabetes to project short-term clinical findings to evaluate long-term outcomes including quality-adjusted life expectancy, complication rates and direct medical costs. Clinical data have been derived from the PREDICTIVE study, an ongoing global post-marketing safety study, for a sub-group of patients with type-1 diabetes receiving long-acting insulin glargine (IGlar) in a basal/bolus treatment regimen at baseline and switched to long-acting insulin detemir (IDet). After 12 weeks of follow up, IDet-based basal/bolus treatment was associated with improvements in HbA1c (0.25%-points lower), reduced risk of hypoglycemic events (by 55%), and decreased body weight (0.27 kg) compared to IGlar-based treatment. Probabilities of complications and HbA1c-dependent adjustments were derived from the DCCT, Framingham, and WESDR studies (amongst others). Costs of treating complications were retrieved from published sources. Total direct costs (complications + treatment costs) were projected over patient lifetimes. Costs and outcomes were discounted at 3.5% per annum. RESULTS: Improved glycemic control, decreased hypoglycemic events and BMI with IDetbased basal/bolus therapy led to fewer diabetes-related complications and an increase in quality-adjusted life expectancy of 0.13 quality-adjusted life years (QALYs). IDet-based therapy was associated with slightly higher lifetime direct costs (€394 per patient) which led to an incremental cost-effectiveness ratio (ICER) of €3031 per QALY gained. CONCLUSIONS: Shortterm clinical benefits associated with IDet-based basal/bolus therapy were projected to lead to improvements in qualityadjusted life expectancy and fewer diabetes related complications than IGlar-based regimens. Incremental cost-effectiveness analysis indicated that, over patient lifetimes, IDet-based combinations would represent good value for money versus IGlar-based therapy in the Austrian setting. (SEK 286, 467 [11, 745] ) than in patients receiving OHAs (SEK 272, 752 [12, 885] ), a difference of SEK 13, 716 [17, 030] , leading to an incremental cost-effectiveness ratio of SEK 32,736 per QALY gained. Sensitivity analysis showed that these findings were robust under variation in a range of assumptions. CONCLUSIONS: Switching to BIAsp 30 was projected to reduce the incidence of diabetes-related complications, and improve life expectancy and quality-adjusted life expectancy, compared to continuation of OHAs in Type-2 diabetes patients. Switching to BIAsp 30 was projected to represent good value for money by internationally accepted standards in the Swedish setting. ) in comparison to neutral protamine Hagedorn insulin + human soluble insulin (NPH/HSI). The aim of this study was to project the long-term clinical and cost outcomes associated with IDet/IAsp versus NPH/HSI basal/bolus therapy in the German setting based on these findings. METHODS: A published, validated and peer-reviewed model that combines Markov sub-models and Monte Carlo simulation was used to simulate the progression of diabetes and its complications (cardiovascular disease, neuropathy, renal and eye disease). Transition probabilities and HbA1c-dependent adjustments were derived from published sources. Baseline cohort characteristics and treatment effect data were based on the clinical study. Direct costs were retrieved from published sources and projected over patient lifetimes from a German National Health care perspective. Costs and clinical benefits were discounted at 3.5% annually. RESULTS: IDet/IAsp treatment was associated with fewer diabetes-related complications, improved life expectancy (0.23 life years gained) and quality-adjusted life expectancy (0.21 QALYs gained) compared to NPH/HSI. Mean total lifetime costs were €3165 per patient higher with IDet/IAsp, leading to incremental cost-effectiveness ratios (ICERs) of €13,761 per life year and €15,071 per QALY gained. CONCLUSIONS: Shortterm clinical benefits in glycemic control, hypoglycemic event rates and BMI associated with IDet/IAsp basal/bolus therapy were projected to lead to fewer complications, improved life expectancy and quality-adjusted life expectancy compared to NPH/HSI. This resulted in ICERs for IDet/IAsp versus NPH/HSI in the range considered to represent good value for money. 4 Medtronic Europe SA, Tolochenaz, Sarl, Switzerland Diabetes Mellitus type-1 (DM1) is a high-incidence, chronic disease that increases morbidity and mortality, in Spain 5000 new diagnosed patients per year have been estimated. DM1 chronic complications are the main cause of resource health care utilization and death among diabetic patients. DM1 is one of the most important causes of death, occupying third place for women and seventh for men in our country. Continuous Subcutaneous Insulin Infusion (CSII) reduces incidence of Diabetesrelated complications when compared with Multiple Daily Injections (MDI) for Type-1. OBJECTIVE: The aim of the study was to project the costs and clinical benefits of CSII vs. MDI in the long term for DM1 patients in Spain. METHODS: An adaptation of the CORE diabetes model was carried out for the Spanish setting. Clinical and economic data were retrieved from published studies and SOIKOSTM Spanish's health care cost database. The analysis was run over a lifetime horizon from a NHS perspective, and direct costs and benefits were actualized to euros 2004 and discounted at 3% annum. RESULTS: Preliminary results showed that treatment with CSII was associated with an improvement in life expectancy (LE) of 0.859 and 0.836 Quality-Adjusted Life-Years (QALY's), compared to MDI. This was accompanied by decreases in cumulative incidence of complications. Mean total lifetime costs were 25,463 € more expensive with CSII treatment vs. MDI. This results in an incremental cost effectiveness ratio of 30,453 €/QALY with CSII compared to MDI group. CONCLUSION: Improvements in glycemic control associated with CSII vs. MDI lead to increase LE and QoL due to reduced incidence of diabetes-related complications. CSII is cost effective compared to MDI according to accepted Spanish threshold. In a recent randomized, controlled clinical study in 447 patients with type-1 diabetes, use of insulin detemir (IDet) versus neutral protamine hagedorn (NPH) insulin in a basal (twice daily)/bolus regimen with insulin aspart (IAsp) as bolus insulin, demonstrated that IDet/IAsp was associated with a risk reduction of 22% for hypoglycemic events (p = 0.029), a reduction of 0.2 kg in body weight (p < 0.001) and decreased systolic blood pressure (SBP) (3 mmHg, p < 0.001) versus NPH/IAsp over 6 months of treatment. No significant difference in HbA1c was noted. The aim of this analysis was to assess the impact of these changes over long-term treatment with IDet/IAsp versus NPH/IAsp. METHODS: A peer-reviewed, validated computer simulation model was used to project these short-term findings to evaluate long-term clinical and cost outcomes. Transition probabilities and risk adjustments were derived from published studies. Baseline cohort characteristics were taken from the clinical trial. Total direct costs (complications + treatment costs) were derived from published sources and projected over patients' lifetimes from a German National Health care perspective. Costs and clinical benefits were discounted at 3.5% annually. RESULTS: Decreased incidence of hypoglycemic events, improved BMI and SBP associated with IDet/IAsp treatment led to fewer diabetes-related complications, increased life expectancy (0.15 years) and improved quality-adjusted life expectancy (0.22 QALYs) compared to NPH/IAsp. Mean total lifetime costs were €1204 per patient higher in the IDet/IAsp treatment arm than in the NPH/IAsp group, leading to incremental cost-effectiveness ratios of €8027 per LYG and €5473 per QALY gained. CONCLUSIONS: Short-term clinical improvements associated with IDet/IAsp were projected to lead to a lower incidence of complications, improved life expectancy and quality-adjusted life expectancy compared to NPH/IAsp. Reductions in the cost of complications partially offset the costs of IDet/IAsp treatment, leading to incremental cost-effectiveness ratios within the range considered to represent good value for money. 
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